OncoBeta’s Research Featured on 9News

OncoBeta’s commitment to advancing dermatological science was recently featured in a national news story on 9News, focusing on our clinical research program. It’s encouraging to see 9news media coverage highlighting innovations in non-melanoma skin cancer (NMSC)

As seen on 9News Australia.

This feature discusses the EPIC-Skin clinical study and the application of Rhenium-SCT®️ for indicated lesions. While the story provides a patient’s perspective, our focus remains on providing the clinical community with robust, evidence-based data to support patient care. Rhenium-SCT®️ is an epidermal radioisotope therapy indicated for biopsy-proven basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) where the lesion depth is ≤3mm. The therapy’s efficacy was evaluated in the EPIC-Skin study, which reported a 94.1% complete response rate at the 12-month follow-up.

For full clinical data, patient selection criteria, and safety information, please refer to the peer-reviewed study publication.

Efficacy, Safety and Patient Experiences of Rhenium-SCT® for Non-Melanoma Skin Cancer

IMPORTANT ADVISORY FOR HEALTHCARE PROFESSIONALS

This content is intended for Australian Healthcare Professionals only. The linked media coverage contains a patient’s personal account. Individual patient experiences and outcomes will vary. This account is not a substitute for clinical evidence and should not be interpreted as a guarantee of results. Healthcare professionals must rely on their own clinical judgment and the full body of evidence when considering Rhenium-SCT®️ for any patient.